Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
December 1, 2025
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2028
Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG
PCX-12
treatment combining radiation therapy with PCX12
Trial Locations (1)
14642
University of Rochester, Rochester
All Listed Sponsors
lead
Haoming (Carl) Qiu
OTHER
NCT06217666 - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) | Biotech Hunter | Biotech Hunter